Morgan Stanley Maintains Overweight on Minimed Group, Raises Price Target to $21
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Kallum Titchmarsh maintains Minimed Group (NASDAQ:MMED) with a Overweight and raises the price target from $19 to $21.
Morgan Stanley analyst Kallum Titchmarsh maintains Minimed Group (NASDAQ:MMED) with a Overweight and raises the price target from $19 to $21.